challenge

challenge - Pharmaceuticals and Life Sciences Pharma 2020:...

Info iconThis preview shows pages 1–6. Sign up to view the full content.

View Full Document Right Arrow Icon
Pharma 2020: Challenging business models Which path will you take? Pharmaceuticals and Life Sciences
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Table of contents Pharma 2020: The vision # Pharma 2020: The vision Which path will you take?* Pharmaceuticals *connectedthinking  Pharma 2020: Virtual R&D Which path will you take? Pharmaceuticals and Life Sciences Pharma 2020: Marketing the future Which path will you take? Pharmaceuticals and Life Sciences Previous publications in this series include: This report, published in June 2008, explores opportunities to improve the R&D process. It proposes that new technologies will enable the adoption of virtual R&D; and by operating in a more connected world the industry, in collaboration with researchers, governments, healthcare payers and providers, can address the changing needs of society more effectively. Published in February 2009, this paper discusses the key forces reshaping the pharmaceutical marketplace, including the growing power of healthcare payers, providers and patients, and the changes required to create a marketing and sales model that is fit for the 21st century. These changes will enable the industry to market and sell its products more cost-effectively, to create new opportunities and to generate greater customer loyalty across the healthcare spectrum. Published in June 2007, this paper highlights a number of issues that will have a major bearing on the industry by 2020. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike. “Pharma 2020: Challenging business models” is the fourth paper in the Pharma 2020 series on the future of the pharmaceutical industry to be published by PricewaterhouseCoopers. This publication highlights how Pharma’s fully integrated business models may not be the best option for the pharma industry in 2020; more creative collaboration models may be more attractive. This paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry. All these publications are available to download at: www.pwc.com/pharma2020
Background image of page 2
Pharma 2020: Challenging business models Table of contents Introduction 1 Profiting alone versus profiting together 1 Harking back to the future 2 Reading the signs 2 Broadening the value proposition and managing the value chain 4 Choosing between different collaborative models 6 The federated model •± The virtual variant of the federated model •± The venture variant of the federated model •± The fully diversified model •± Charting a successful course 12 Conclusion 13 Acknowledgements 15 References 17
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Table of contents
Background image of page 4
Pharma 2020: Challenging business models 1 Introduction The pharmaceutical marketplace is undergoing huge changes, as we indicated in “Pharma 2020: The vision”, the White Paper PricewaterhouseCoopers* published in June 2007.
Background image of page 5

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 6
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 24

challenge - Pharmaceuticals and Life Sciences Pharma 2020:...

This preview shows document pages 1 - 6. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online